{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:42:07Z","timestamp":1792089727010,"version":"4.4.0"},"reference-count":35,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"9","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Background: This study aimed to assess the clinical utility of serum tumour markers - carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 50, CA19-9, CA72-4, and the cytokeratin 19 fragment (CYFRA21-1) - for early detection and prognostic evaluation in colon cancer. Methods: A total of 50 patients diagnosed with colon cancer and 50 healthy individuals were enrolled. Serum levels of CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 were quantified and compared between groups. Correlations with tumour staging, recurrence, and metastasis were also analysed. Results: All five serum markers were significantly elevated in colon cancer patients compared to controls (P&amp;lt; 0.05). Marker levels were notably higher in advanced-stage cases (stages III-IV) than in early-stage disease (stages I-II) (P&amp;lt; 0.05). Following surgery, marker levels declined significantly (P&amp;lt; 0.05), except in patients with recurrence or metastasis, who showed elevated preoperative values (P&amp;lt; 0.05). Combined detection yielded significantly higher positive detection rates, sensitivity, and specificity than individual marker assessments (P&amp;lt; 0.05). Conclusions: CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 are clinically relevant markers for the detection, staging, and prognostic prediction of colon cancer. Combined serum marker analysis substantially improves diagnostic precision and supports early screening and outcome assessment.<\/jats:p>","DOI":"10.5937\/jomb0-55648","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T07:05:21Z","timestamp":1754031921000},"page":"1910-1917","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostic and prognostic value of serum markers CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 in colon cancer"],"prefix":"10.5937","volume":"44","author":[{"given":"Ze","family":"Song","sequence":"first","affiliation":[{"name":"The Seventh Affiliated Hospital, Sun Yat-sen University, Department of Oncology, Shenzhen, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tang","sequence":"additional","affiliation":[{"name":"Southern University of Science and Technology, Department of Vascular and Interventional Oncology, Shenzhen, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[{"name":"Huizhou Municipal Centre Hospital, Office of GCP, Department of Pharmacy, Huizhou City, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[{"name":"Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Department of Radiology, Changsha city, Hunan province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Seventh Affiliated Hospital, Sun Yat-sen University, Department of Interventional Radiology, Shenzhen, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lu W, Jin X L, Yang C, Du P Jiang FQ, Ma JR Yang J, Xie P Zhang Z. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomised controlled trial. Cancer Biol Ther 2017; 18(6): 433-8;","DOI":"10.1080\/15384047.2017.1323589"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Majdop S, Skornick Y, Avital S, Berkovich L. Phospholipase D activation mediates growth and migration of colon cancer cells interacting with cancer-associated fibroblasts. Cell Mol Biol (Noisy-le-grand) 2018; 64(14): 84-8;","DOI":"10.14715\/cmb\/2018.64.14.14"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Wu Z, Lu Z, Li L, Ma M, Long F Wu R, Huang L, Chou J, Yang K, Zhang Y, Li X , Hu G, Zhang Y, Lin C. Identification and validation of ferroptosis-related LncRNA signatures as a novel prognostic model for colon cancer. Front Immunol 2022; 12: 783362;","DOI":"10.3389\/fimmu.2021.783362"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Guo JN, Chen D, Deng SH, Huang JR, Song JX , Li XY, Cui BB, Liu YL. Identification and quantification of immune infiltration landscape on therapy and prognosis in leftand right-sided colon cancer. Cancer Immunol Immunother 2022; 71(6): 1313-30;","DOI":"10.1007\/s00262-021-03076-2"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Zhang HC, Deng SH, Pi YN , Guo JN, Xi H, Shi X , Yang X F Zhang BM, Xue WN, Cui BB, Liu YL. Identification and validation in a novel quantification system of ferroptosis patterns for the prediction of prognosis and immunotherapy response in leftand right-sided colon cancer. Front Immunol 2022; 13: 855849;","DOI":"10.3389\/fimmu.2022.855849"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Yoshino T, Argil\u00e9s G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti BK, Ahn JB, Faud I, Chee CE, Yeh KH, Lin PC, Chua C, Hasbullah HH, Lee MA, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Ann Oncol 2021; 32(12): 1496-510;","DOI":"10.1016\/j.annonc.2021.08.1752"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Vogel JD, Felder SI, Bhama AR, Hawkins AT, Langenfeld SJ, Shaffer VO, Thorsen AJ, Weiser MR, Chang GJ, Lightner AL, Feingold DL, Paquette IM. The American society of colon and rectal surgeons clinical practice guidelines for the management of colon cancer. Dis Colon Rectum 2022; 65(2): 148-77;","DOI":"10.1097\/DCR.0000000000002323"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Shi W, Men L, Pi X , Jiang T, Peng D, Huo S, Luo P , Wang M, Guo J, Jiang Y, Peng L, Lin L, Li S, Lv J. Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL 6\/ s TaT 3 signaling pathway. Int J Oncol 2021; 59(6): 99;","DOI":"10.3892\/ijo.2021.5279"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Khan H, Alam W, Alsharif KF, Aschner M, Pervez S, Saso L. Alkaloids and colon cancer: molecular mechanisms and therapeutic implications for cell cycle arrest. Molecules 2022; 27(3): 920;","DOI":"10.3390\/molecules27030920"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Mukherjee AG, Wanjari UR, Bradu P Murali R, Kannampuzha S, Loganathan T, C GPD, Prakash BPA, Renu K, Dey A, Vellingiri B, Valsala Gopalakrishnan A. The crosstalk of the human microbiome in breast and colon cancer: a metabolomics analysis. Crit Rev Oncol Hematol 2022; 176: 103757;","DOI":"10.1016\/j.critrevonc.2022.103757"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Lwin TM, Turner MA, Amirfakhri S, Nishino H, Debie P , Cosman BC, Hoffman RM, Hernot S, Bouvet M. Rapid tumour-labeling kinetics with a site-specific near-infrared anti-CEA nanobody in a patient-derived orthotopic xenograft mouse model of colon cancer. J Surg Oncol 2021; 124(7): 1121-7;","DOI":"10.1002\/jso.26623"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Chen T Wang Y Nan Z, Wu J, Li A, Zhang T, Qu X , Li C. Interaction between macrophage extracellular traps and colon cancer cells promotes colon cancer invasion and correlates with unfavorable prognosis. Front Immunol 2021; 12: 779325;","DOI":"10.3389\/fimmu.2021.779325"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Morimoto Y Takahashi H, Arita A, Itakura H, Fujii M, Sekido Y, Hata T, Fujino S, Ogino T, Miyoshi N, Uemura M, Matsuda C, Yamamoto H, Mizushima T, Doki Y Eguchi H. High postoperative carcinoembryonic antigen as an indicator of high-risk stage II colon cancer. Oncol Lett 2022; 23(5): 167;","DOI":"10.3892\/ol.2022.13287"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Pang X , Xu B, Lian J, Wang R, Wang X , Shao J, Tang S, Lu H. Real-world survival of colon cancer after radical surgery: a single-institutional retrospective analysis. Front Oncol 2022; 12: 914076;","DOI":"10.3389\/fonc.2022.914076"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Yu K, Qiang G, Peng S, Kuang R. Potential diagnostic value of the hematological parameters lymphocyte-monocyte ratio and hemoglobin-platelet ratio for detecting colon cancer. J Int Med Res 2022; 50(9): 3000605221122742;","DOI":"10.1177\/03000605221122742"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Zhou H, Wang S, Cai Z, Qiu E, Chen Q, Rao X , Han S, Li Z. Adjuvant chemotherapy benefits on patients with elevated carcinoembryonic antigen in stage IIA colon cancer: a SEER-based analysis. Int J Colorectal Dis 2022; 37(12): 2481-9;","DOI":"10.1007\/s00384-022-04278-5"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Hao Z, Parasramka S, Chen Q, Jacob A, Huang B, Mullett T Benson AB. Neoadjuvant versus adjuvant chemotherapy for resectable metastatic colon cancer in non-academic and academic programs. Oncologist 2023; 28(1): 48-58;","DOI":"10.1093\/oncolo\/oyac209"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Liu Y Zhang H, Zheng M, Wang C, Hu Z, Wang Y Xiong H, Fan B, Wang Y, Hu H, Tang Q, Wang G. Nomogram to predict the occurrence and prognosis of distant metastasis in T1N0 colon cancer: a SEER data-based study. Int J Gen Med 2021; 14: 9131-43;","DOI":"10.2147\/IJGM.S335151"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Minnix M, Kujawski M, Poku E, Yazaki PJ, Wong JYC, Shively JE. Improved tumour responses with sequential targeted alpha followed by IL2 immunocytokine therapies in treatment of CEA positive breast and colon tumours in CEA transgenic mice. J Nucl Med 2022; 63(12): 1859-64;","DOI":"10.2967\/jnumed.122.264126"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"AbdelMageed M, Ismail HTH, Olsson L, Lindmark G, Hammarstr\u00f6m ML, Hammarstr\u00f6m S, Sitohy B. Clinical significance of stem cell biomarkers EpCAM, LGR5 and LGR4 mRNA levels in lymph nodes of colon cancer patients. Int J Mol Sci 2021; 23(1): 403;","DOI":"10.3390\/ijms23010403"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Kasahara K, Enomoto M, Udo R, Tago T, Mazaki J, Ishizaki T, Yamada T, Nagakawa Y, Katsumata K, Tsuchida A. Prognostic value of preoperative high-sensitivity modified Glasgow prognostic score in advanced colon cancer: a retrospective observational study. BMC Cancer 2022; 22(1): 20;","DOI":"10.1186\/s12885-021-09113-8"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Meng G, Yang S, Chen F Survival for patients with metastatic colon cancer underwent cytoreductive colectomy in the era of rapid development of anticancer drugs: a real-world analysis based on updated population dataset of 2004-2018. Front Pharmacol 2022; 13: 983092;","DOI":"10.3389\/fphar.2022.983092"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sawayama H, Miyamoto Y, Ogawa K, Ohuchi M, Tokunaga R, Yoshida N, Kobayashi H, Sugihara K, Baba H. Index of estimated benefit from lymph node dissection for stage I-III transverse colon cancer: an analysis of the JSCCR database. Langenbecks Arch Surg 2022; 407(5): 2011-9;","DOI":"10.1007\/s00423-022-02525-5"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Ishii K, Watanabe J, Goto K, Suwa Y, Nakagawa K, Suwa H, Ozawa M, Ishibe A, Kunisaki C, Endo I. The prognostic significance of apical lymph node metastasis in patients with high-risk stage III colon cancer. Sci Rep 2022; 12(1): 2059;","DOI":"10.1038\/s41598-022-06054-5"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Weinberg BA, Winslow ER, Bayasi M, Krainock MR, Olshan PM, Billings PR, Aleshin A. Early detection of circulating tumour DNA postoperatively enables discovery of resectable metastatic disease in a patient with colon cancer. Case Rep Oncol 2021; 14(3): 1748-53;","DOI":"10.1159\/000520743"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Wang Y Zhou Y Lin H, Chen H, Wang S. Paeoniflorin inhibits the proliferation and metastasis of ulcerative colitis-associated colon cancer by targeting EGFL7. J Oncol 2022; 2022: 7498771;","DOI":"10.1155\/2022\/7498771"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Murray NP Villalon R, Hartmann D, Rodriguez PM, Aedo S. Improvement in the neutrophil-lymphocyte ratio after combined fluorouracil, leucovorina and oxaliplatino based (FOLFOX) chemotherapy for stage III colon cancer is associated with improved minimal residual disease and outcome. Asian Pac J Cancer Prev 2022; 23(2): 591-9;","DOI":"10.31557\/APJCP.2022.23.2.591"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Pedrazzani C, Turri G, Marrelli D, Kim HJ, Park EJ, Spolverato G, Foppa C, Spinelli A, Pucciarelli S, Baik SH, Choi GS. Prediction of metachronous peritoneal metastases after radical surgery for colon cancer: a scoring system obtained from an international multicenter cohort. Ann Surg Oncol 2022; 29(12): 7896-906;","DOI":"10.1245\/s10434-022-12097-9"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Riffet M, Eid Y Faisant M, Fohlen A, Menahem B, Alves A, Dubois F Levallet G, Bazille C. Deciphering promoter hypermethylation of genes encoding for RASSF\/hippo pathway reveals the poor prognostic factor of RASSF2 gene silencing in colon cancers. Cancers (Basel) 2021; 13(23): 5957;","DOI":"10.3390\/cancers13235957"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Teijeira A, Migueliz I, Garasa S, Karanikas V, Luri C, Cirella A, Olivera I, Canamero M, Alvarez M, Ochoa MC, Rouzaut A, Rodriguez-Ruiz ME, Sanmamed MF Klein C, Umana P Ponz M, Bacac M, Melero I. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers. Theranostics 2022; 12(3): 1373-87;","DOI":"10.7150\/thno.63359"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Fleming CA, Jordan P O'Leary DP Corrigan MA, Wang JH, Redmond HR Perioperative cell-free DNA trends predict recurrence of non-metastatic colorectal cancer significantly earlier than CEA trends over the first 2 years postoperatively in stage II and stage III colon cancer. Int J Colorectal Dis 2022; 37(5): 1119-26;","DOI":"10.1007\/s00384-022-04133-7"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Jue W, Lulu L, Yan Z, Gu S. Expression levels and diagnostic value od serum. J Med Biochem 2024; 43 (2): 250-6;","DOI":"10.5937\/jomb0-44745"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Ogata S, Fujita F, Fujiyoshi K, Sudou T, Yoshida T, Koushi K, Murotani K, Yamauchi S, Sugihara K, Akagi Y Prognostic value of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels for adjuvant chemotherapy in stage II colorectal cancer: a nationwide multicenter retrospective study. J Anus Rectum Colon 2022; 6(4): 249-58;","DOI":"10.23922\/jarc.2022-020"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Wang H, Jin W, Wan C, Zhu C. Diagnostic value of combined detection of CA72-4, CA19-9, and carcinoembryonic antigen comparing to CA72-4 alone in gastric cancer: a systematic review and meta-analysis. Transl Cancer Res 2022; 11(4): 848-56;","DOI":"10.21037\/tcr-22-537"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Luo K, Zhao C, Luo Y, Pan C, Li J. Electrochemical sensor for the simultaneous detection of CA72-4 and CA19-9 tumour markers using dual recognition via glycosyl imprinting and lectin-specific binding for accurate diagnosis of gastric cancer. Biosens Bioelectron 2022; 216: 114672;","DOI":"10.1016\/j.bios.2022.114672"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Dijagnosti\u010dka i prognosti\u010dka vrednost serumskih markera CEA, CA50, CA19-9, CA72-4 i CYFRA21-1 kod karcinoma debelog creva"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2025\/1452-82582509910S.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:52:45Z","timestamp":1767703965000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582509910S"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-55648","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}